Opko Health Inc. (NASDAQ:OPK) through its subsidiaries, OPKO Pharmaceuticals LLC and Eirgen Pharma Limited, Ireland has read the notification forwarded by European Commission. The notification has everything to do with OPKO’s oligonucleotide-based AntagoNAT (CUR-1916) which happens to be an important medicinal product for assisting patients suffering from Dravet Syndrome.
The Orphan Drug Application is under close scrutiny from U.S FDA and of course this is in a move to ensure that patients out there are served with standard and effective drugs to help treat their conditions appropriately.
At this particular moment, we can’t lay a hand on any given treatment as the perfect t or approved treatment for persons suffering from Dravet Syndrome. In As a much as there are so many research institutions out there looking for the various ways to treat the condition, none has gotten approved by FDA. However, it is important that patients around the globe appreciate the efforts that are being redirected into research and hope for the best as well!
OPKO platform technology is putting to test a number of clinical substances in efforts to try and interfere with regulatory gene expression. The motive here is to way all the possible options that would result in the production of endogenous functional proteins. It was in the year 2011 when OPKO acquired the AntagoNAT technology which it hoped to work on in a big way.
OPKO’s Miami research laboratories were quite instrumental in carrying out further research and the top professional that was at the moment overseeing the experiment was OPKO’s Chief Technical Officer who was at the same time serving in a higher capacity as the body’s Vice Chairman.
OPKO, which happens to be one of the Best Biotech Stocks, has done quite much in the field of research considering that it has by this moment studied over 250n genes. Not quite a lot of companies have gone this far as a matter of fact! In the course of the research, OPKO has been able to learn much to do with the genes under study as well as the natural antisense transcripts in the associated regulatory pathways.
One of the oligonucleotide compounds has been approved by FDA but it works by correcting gene defects or by regulating transcription. Most of the Top Biotech Stocks have leant about the new development and of course are working harder.